Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.69 |
| ▸ | RAD52 | P43351 | 2/20 | 0.69 |
| ▸ | MAPT | P10636 | 2/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.69 |
| ▸ | GFER | P55789 | 1/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.69 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | ESRRB | O95718 | 2/20 | 0.56 |
| ▸ | ESRRG | P62508 | 2/20 | 0.56 |
| ▸ | ESR1 | P03372 | 1/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.55 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | HTR7 | P34969 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL82263 | 0.93 | GAA (0.61) | GAARAD52MAPTKDM4EGFER | |
| SCHEMBL20376700 | 0.88 | MAPT (0.55) | GAARAD52MAPTKDM4EGFER | |
| SCHEMBL7105773 | 0.84 | ADRB1 (0.70) | GAAMAPTKDM4EGFERSMN1; SMN2 | |
| SCHEMBL10063748 | 0.84 | ADRB1 (0.70) | GAAMAPTKDM4EGFERSMN1; SMN2 | |
| SCHEMBL3414344 | 0.84 | ADRB1 (0.70) | GAAMAPTKDM4EGFERSMN1; SMN2 | |
| SCHEMBL81904 | 0.84 | DRD2 (0.70) | GAARAD52MAPTKDM4EGFER | |
| SCHEMBL14924468 | 0.83 | KMT2A (0.67) | GAARAD52MAPTKDM4EGFER | |
| SCHEMBL24452939 | 0.82 | MAPT (0.67) | GAARAD52MAPTKDM4EGFER | |
| SCHEMBL578273 | 0.82 | GAA (0.67) | GAARAD52MAPTKDM4EGFER | |
| SCHEMBL10891766 | 0.82 | KMT2A (0.71) | GAARAD52MAPTKDM4EGFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11827640-B2 | Substituted pyrazolo[1,5-a]pyrimidines as CFTR modulators | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2023-11-28 | — | — | US | disclosed |
| EP-4230204-A1 | THIOBENZIMIDAZOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND USE THEREOF | Korea University Research and Business Foundation (KR) | 2023-08-23 | — | — | EP | disclosed |
| WO-2023078813-A1 | HETEROBIFUNCTIONAL MOLECULES AS TEAD INHIBITORS | MERCK PATENT GMBH (DE) | 2023-05-11 | — | — | WO | disclosed |
| US-20220305016-A1 | USES OF SALT-INDUCIBLE KINASE (SIK) INHIBITORS FOR TREATING OSTEOPOROSIS | THE GENERAL HOSPITAL CORPORATION (US) | 2022-09-29 | — | — | US | disclosed |
| EP-3480186-B1 | NOVEL ARYL ETHENE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME AS ACTIVE INGREDIENT | NOVMETAPHARMA CO LTD (KR) | 2022-06-15 | — | — | EP | disclosed |
| WO-2022086110-A1 | THIOBENZIMIDAZOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND USE THEREOF | 고려대학교 산학협력단 | 2022-04-28 | — | — | WO | disclosed |
| EP-3459936-B1 | NOVEL ARYL ETHANE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | DAEGU GYEONGBUK MEDICAL INNOVATION FOUND (KR) | 2022-04-27 | — | — | EP | disclosed |
| WO-2021254389-A1 | PYRAZOLO[3,4-D]PYRIMIDINE-3-KETONE DERIVATIVE AS WEE-1 INHIBITOR | 微境生物医药科技(上海)有限公司 | 2021-12-23 | — | — | WO | disclosed |
| US-20210332046-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR SILENT AGONISTS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-10-28 | — | — | US | disclosed |
| US-11155551-B2 | Nicotinic acetylcholine receptor silent agonists | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2021-10-26 | — | — | US | disclosed |
| WO-2008075068-A2 | ACYLAMINOPYRAZOLES AS FGFR INHIBITORS | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | WO | disclosed |
| US-20080153812-A1 | Heterocyclic amides as anticancer agents | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | US | disclosed |
| US-20080153812-A1 | Heterocyclic amides as anticancer agents | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | US | disclosed |
| US-7342115-B2 | Binding antagonist and arylpyridine for antiinflammatory agents, cardiovascular disorders and antagonist or agonist and for immunology | NEUROGEN CORPORATION (US) | 2008-03-11 | — | — | US | disclosed |
| US-7300945-B2 | Benzimidazole and pyridylimidazole derivatives | NEUROGEN CORPORATION (US) | 2007-11-27 | — | — | US | disclosed |
| US-20070207999-A1 | New Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-09-06 | — | — | US | disclosed |
| US-20070060570-A1 | Sulfopyrroles | TALEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-03-15 | — | — | US | disclosed |
| US-7166572-B1 | Cyclohexapeptide compounds, processes for their production and their use as a pharmaceutical | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2007-01-23 | — | — | US | disclosed |
| US-7166572-B1 | Cyclohexapeptide compounds, processes for their production and their use as a pharmaceutical | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2007-01-23 | — | — | US | disclosed |
| WO-2003020278-A1 | CYSTEINE PROTEASE INHIBITORS WITH 2-CYANO-4-AMINO-PYRIMIDINE STRUCTURE AND CATHEPSIN K INHIBITORY ACTIVITY FOR THE TREATMENT OF INFLAMMATIONS AND OTHER DISEASES | NOVARTIS AG (CH) | 2003-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11827640-B2 | Substituted pyrazolo[1,5-a]pyrimidines as CFTR modulators | PDE4A, PDE4B, PDE5A | GAA 447/4885RAD52 4767/4885MAPT 4661/4885 |
| US-11155551-B2 | Nicotinic acetylcholine receptor silent agonists | CHRNA7, CHRNA2, CHRNE | GAA 3751/4885RAD52 3251/4885MAPT 2570/4885 |
| US-20070060570-A1 | Sulfopyrroles | TYK2, ARSA, SULT2A1 | GAA 3347/4885RAD52 1340/4885MAPT 4766/4885 |
| US-20220305016-A1 | USES OF SALT-INDUCIBLE KINASE (SIK) INHIBITORS FOR TREATING OSTEOPOROSIS | SOST, SIK2, SIK1 | GAA 3066/4885RAD52 4752/4885MAPT 1864/4885 |
| US-20080153812-A1 | Heterocyclic amides as anticancer agents | HDAC1, HDAC11, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | GAA 334/4885RAD52 3653/4885MAPT 3682/4885 |
| US-20210332046-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR SILENT AGONISTS | CHRNA7, CHRNA2, CHRNE | GAA 3751/4885RAD52 3251/4885MAPT 2570/4885 |
| US-20070207999-A1 | New Compounds | CCNA1, MKI67, CCNT1 | GAA 329/4885RAD52 4653/4885MAPT 3181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.